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BrainLoss of dopamine (DA) homeostasis may be a contributing factor to cell damage in Parkinson's disease (PD).
Past studies showing deleterious effects of DA on mitochondrial function, however, have been inconsistent
raising questions about mitochondria as a downstream target for DA. Issues such as the dopamine species i.e.,
reduced or oxidized, time of exposure and the effect of major metabolites such as 3,4-dihydrophenylacetic
acid (DOPAC) may contribute to the disparate ﬁndings. The present study used isolated, lysed rat brain
mitochondria to characterize the effects of oxidized or reduced DA and DOPAC on complex activities of the
electron transport chain (ETC). Time of exposure and quantitation of reduced or oxidized catachols for DA and
DOPAC were monitored for all experiments. Reduced DA and DOPAC with or without a 30 min preincubation
had no affect on NADH oxidase activity which monitors the activities of complexes I, III and IV. Complex II
activity was inhibited by reduced DA (≥500 μM), but not by reduced DOPAC and was signiﬁcantly attenuated
by SOD suggesting reactive oxygen species involvement. In contrast, fully oxidized DA and DOPAC dose
dependently inhibited NADH oxidase, complex I and complex III activities with IC50s in the 50–200 μM range.
No preincubation was required for inhibition with the catechols when they were fully oxidized. Oxidized DA
inhibited complex I only when exposure occurred during stimulated electron ﬂow, suggesting covalent
binding of quinones to proteins within active sites of the complex. In intact, well coupled mitochondria,
extramitochondrial DA was shown to access the mitochondrial matrix in a dose, time and energy-dependent
fashion. The ﬁndings suggest that many of the reported inconsistencies with regards to the effects of DA and
DOPAC on ETC function can be attributed to the oxidized state of the catechol at the time of exposure. In
addition, the ﬁndings provide possible downstream targets for DA that could contribute to the vulnerability of
dopaminergic neurons in PD.enylacetic acid; DAH, reduced
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Parkinson's disease (PD) is a late-onset neurodegenerative disease
inwhich themajor feature is the loss of dopamine (DA) neurons in the
substantia nigra. DA has been postulated to contribute to the cellular
damage and degeneration that occurs in PD [1–3] through loss of DA
homeostasis resulting in excess levels of DA and its metabolites. DA
metabolism by monoamine oxidase (MAO) results in the formation of
the DA metabolites 3,4-dihydroxyphenylacetic acid (DOPAC), ammo-nia, and hydrogen peroxide (H2O2) , which can cause oxidative stress
damage and subsequent cell death [4]. Alternatively, DA can undergo
oxidation, to form a quinone and other downstream-oxidized prod-
ucts [5–7]. DA can also oxidize to form hydroquinones and semi-
quinone radical intermediates [8,9]. DA derived o-quinones in general
are highly reactive electrophiles that may readily bind covalently to
cellular nucleophiles such as DNA, glutathione (GSH), cysteine and
reduced sulfhydryl groups on protein cysteinyl residues. Such protein
adducts can result in protein dysfunction [10]. Elevation in 5-S-
cysteinly-dopamine (5-S-Cys-DA) has been found in human sub-
stantia nigra [11], while in rodents exposed to exogenous DA, an
increase in DA-protein adducts has been observed in vivo [12].
Mitochondrial dysfunction is also thought to contribute to the
etiology of PD [13]. In PD brain as well as in blood platelets andmuscle
biopsy from PD patients, studies have shown decreases in the activity
of the mitochondrial electron transport chain (ETC) complex I [14,15],
and decreases in combined complex II/III and in the Kreb's cycle
enzyme α-ketoglutarate-dehydrogenase [16,17]. In animal studies,
we and others have shown that DA can have direct effects on intact
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drial permeability pore transition and uncoupling [3,18,19], raising
the possibility that loss of DA homeostasis can contribute to and
exacerbate mitochondrial dysfunction. Studies to pinpoint the site of
action for DA toxicity in mitochondrial function, however, have been
incomplete and report contradictory results that range from no effect
of DA on mitochondrial function [20] to low IC50s of 8–12 μM for
inhibition of complex I [21,22]. Inconsistencies among these studies
have raised questions regarding DA and mitochondrial function with
respect to the DA species i.e. reduced or oxidized (DAH, DAQ respec-
tively) that may cause inhibition, the sites within the ETC that are
affected and if the major DA metabolite, DOPAC, reduced or oxidized
(DOPAC-H, DOPAC-Q), may also affect mitochondrial function.
The present study was, therefore carried out to characterize the
effects of DA and DOPAC on individual ETC complexes paying
attention to 2 variables likely contributing to the inconsistencies in
prior studies, i.e., the extent of quinone formation and the time of
exposure to the catechols. Findings from the study help to reconcile
disparate past reports and provide insight into ongoing cellular
sequelae that contributes to dopamine cell loss in PD.
2. Materials and methods
2.1. Materials
All chemicals were obtained from Sigma Chemical Co. (St. Louis,
MO, U.S.A.).
2.2. Animals
All experiments were conducted in Sprague Dawley rats from
Charles River Laboratories (Wilmington, MA, USA) in accordance
with the National Institutes of Health Guide for the Care and Use of
Laboratory Animals. The local Animal Care Committee approved all
procedures. Rats were housed in pairs at 20–22 °C on a 12 h light–
dark cycle with food and water available ad libitum.
2.3. Mitochondrial isolation
Mitochondrial isolation followed the procedure of Clark and
Nicklas, [23] as we have reported in detail previously [18,19]. For
studies using intact mitochondria, O2 consumption was monitored
and the respiratory control ratio (RCR), calculated as we have
previously reported [18]. The mitochondrial RCR for studies using
intact mitochondria was N8 indicating well coupled mitochondria at
the time of assay. For studies using lysedmitochondria, the mitochon-
dria were aliquoted and stored at −80 °C. Five freeze thaw cycles
were conducted to lyse mitochondria prior to assay of ETC activities.
All uptake and activity assay results were from 3 separate experi-
ments run in duplicate.
2.4. DAH/DAQ and DOPAC-H/DOPAC-Q solutions
DAH and DOPAC-H solutions were made in ice cold HPLC water
and kept on ice. The solutions weremonitored at 480 nm and 400 nm,
respectively, to verify any quinone formation [8,24]. DAQ and DOPAC-
Q solutions were made in phosphate buffer pH 8.0 and kept at room
temperature. A standard curve generated from different concentra-
tions of DA oxidized by [25U] tyrosinase was used to quantify the
desired DAQ concentrations. A standard curve for DOPAC-Q was
generated from different concentrations of DOPAC oxidized by [250U]
tyrosinase and used to quantify DOPAC-Q. DA used in the ETC assays
was air oxidized rather than oxidized by tyrosinase due to interactions
between tyrosinase mediated DAQ formation and the oxidation of
NADH. The DAQ concentration was monitored at 480 nm until the
desired absorbance for corresponding DAQ concentration on thestandard curve was reached. For example, 50 μM DAQ had an
absorbance of 0.16, whereas 100 μm DAQ had an absorbance of
0.31. Oxidized DOPAC used in the ETC assays was oxidized by tyro-
sinase due to the low auto-oxidation of DOPAC. Moreover, tyrosinase-
mediated-DOPAC-Q formation did not interfere with NADH oxidation.
The DOPAC-Q concentration was monitored at 400 nm until the
desired absorbance for the corresponding DOPAC-Q concentration on
the standard curve was reached.
2.5. NADH-oxidase
The oxidation of NADH was measured spectrophotometrically
by following the decrease in absorbance at 340 nm. Activity was
expressed as nmol of NADH oxidation/min/mg protein (E=6.81
mM−1·cm−1 ). The activity assay was modiﬁed from Ragan et al. [25]
Brieﬂy, the assay medium contained K2HPO4 (20 mM) pH 7.4, and
EDTA (0.5 mM). To verify that NADH oxidation was associated with
ETC activity, a parallel control with rotenone (10 μM) was run.
Activity was inhibited by ≥90% with rotenone and results reported as
the rotenone sensitive activity. DAH/DAQ or DOPAC-H/DOPAC-Q was
monitored at 480 nm and 400 nm, respectively, to verify quinone
content just prior to use. NADH (0.13 mM) was then added and the
absorbance change was recorded for 2 min. Following this, mitochon-
dria (50 μg/ml) were added, and enzyme-catalyzed NADH oxidation
was measured for 3–5 min. Activity was measured in mitochondria
either with or without a 30 min preincubation with DAH/DOPAC-H or
DAQ. In control studies, DAH and DOPAC-H did not promote NAD+
reduction and, therefore, did not produce artifacts in either the NADH-
oxidase or complex I assay.
2.6. Complex I: NADH: ubiquinone oxidoreductase
The complex I assay was modiﬁed from Birch-Machin et al. [26]
andmeasured spectrophotometrically the decrease in absorbance due
to the oxidation of NADH at 340 nm. Activitywas expressed as nmol of
NADH oxidation/min/mg protein. Brieﬂy, the assay medium con-
tained K2HPO4(20 mM) pH 7.4, EDTA(0.5 mM), coenzyme Q1
(0.065 mM), antimycin A (0.002 mg/ml) to inhibit complex III and
potassium cyanide (KCN) (2 mM) to inhibit complex IV. The reaction
was initiated by the addition of NADH (0.13 mM) and the absorbance
change was recorded for 2 min. Mitochondria (50 μg/ml) were then
added and enzyme-catalyzed NADH oxidation was measured for 3–
5 min. A parallel control with rotenone (10 μM) was run to deﬁne
activity speciﬁc to complex I. Rotenone inhibited complex I activity by
≥95% and was reported as the rotenone sensitive activity. DAH/DAQ
or DOPAC-H/DOPAC-Q was monitored for quinone content as stated
above just prior to use. Complex I activity was measured in mito-
chondria either with or without a 30 min preincubation with DAH/
DOPAC-H or DAQ.
2.7. Complex II: succinate: ubiquinone oxidoreductase
Complex II speciﬁc activity was measured by following the
reduction of 2,6-dichlorophenolindophenol (DCPIP) at 600 nm.
Activity was expressed as nmol of DCPIP reduction/min/mg protein
(E=19.1 mM−1·cm−1). Complex II assay was modiﬁed from Birch-
Machin et al. [26]. Brieﬂy, the assay medium contained K2HPO4
(25 mM) pH 7.4, EDTA(0.1 mM), KCN (2 mM), rotenone (10 μM),
antimycin A(0.002 mg/ml), succinate (25 mM) and mitochondria
(50 μg/ml) and incubated for 15 min at room temperature. DCPIP
(0.050 mM) was added and absorbance change was recorded for
2 min. This was the non-enzymatic reduction rate of DCPIP and was
subtracted from the enzymatic rate. Coenzyme Q1 (0.065 mM) was
then added to initiate the reaction and the enzyme-catalyzed reduc-
tion of DCPIP was measured for 3–5 min. A parallel control with the
complex II inhibitor malonate (10 mM) and mitochondria was also
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studies, without mitochondria, DAH and DOPAC-H were found to
reduce DCPIP. Since the complex II assay measures the reduction of
DCPIP this added to the forward reaction and masked inhibition. To
correct for the artifact, the non-enzymatic rate determined in the
presence of DAH or DOPAC-H plus DCPIP and malonate but lacking
mitochondria was subtracted from samples with mitochondria. DAQ
and DOPAC-Q did not create an artifactual interference however, in
order to maintain consistency of assay conditions parallel controls
with inhibitors and DAQ/DOPAC-Q were also run. Complex II activity
was the malonate sensitive activity.
2.8. Complex III: ubiquinol: ferricytochrome C oxidoreductase
Complex III speciﬁc activity was measured by monitoring at
550 nm the reduction of oxidized cytochrome C (III) to reduced
cytochrome C (II). Activity was expressed as nmol of cytochrome C
reduction/min/mg protein (E=19 mM−1·cm−1). The complex III
assay was modiﬁed from Krahenbuhl et al. [27]. Brieﬂy, cytochrome C
was ﬁrst oxidized by exposure to O2 gas. The reaction medium
contained K2HPO4 (25 mM) pH 7.4, MgCl2(5.0 mM), KCN(2.0 mM),
bovine serum albumin (BSA, 2.5 mg/ml), dodecyl maltoside(0.44 mg/
ml), rotenone(10 μM), decylubiquinol (0.15 μM/ml) (see below), and
oxidized cytochrome C (III) (80 μM). Mitochondria (10 μg/ml) were
preincubated with catechols for 15 min at room temperature, then
added to the assay at 10 μg/ml to initiate the reaction and the
enzymatic reduction of cytochrome C (III) was measured for 3–5 min.
A parallel control with complex III inhibitors myxothiazol (60 μM)
and antimycin A (0.002 mg/ml) inhibited the activity by ≥95%.
Complex III activity was the inhibitor sensitive rate. DAH/DAQ or
DOPAC-H/DOPAC-Q was monitored for quinone formation just prior
to use. In control studies, in the absence of mitochondria DAH or
DOPAC-H but not their oxidized counterparts was found to pass
electrons to oxidized cytochrome C (III) to produce reduced cyto-
chrome C (II). This added to the forward reaction and created an
artifact that masked inhibition. Corrections to the rate made by
subtraction of the nonenzymatic rate could not be made as reaction
rates were variable and inconsistent (see Results). DAQ and DOPAC-Q
did not react with cytochrome C, however, for consistency and to
control for any reduced catechols present when DAQ or DOPAC-Qwas
added to mitochondria, rates were run in the presence or absence of
inhibitors. Decylubiquinol was synthesized according to Krahenbuhl
et al. [27] by reduction of decylubiquinone (10 μmol) with sodium
borohydride (NaBH4) and the solution stored at −20 °C under light
protection.
2.9. Complex IV: ferrocytochrome C oxidase: oxygen oxidoreductase
Complex IV speciﬁc activity was measured by following the
oxidation of reduced cytochrome C (II) to oxidized cytochrome C
(III) at 550 nm. Activity was expressed as nmol of cytochrome C
oxidized/min/mg protein (E=19 mM−1·cm−1). The complex IV
assay was modiﬁed from Birch-Machin et al. [26]. Brieﬂy, the assay
medium contained K2HPO4 (25 mM) pH 7.4, reduced cytochrome C
(II) (80 μM) (see below) and dodecyl maltoside (0.44 mg/ml).
Mitochondria (50 μg/ml) were added to initiate the reaction and the
enzymatic oxidation of cytochrome C (II) was measured for 3–5 min.
In some preparations, mitochondria (50 μg/ml) were pre-incubated
with DAQ or DOPAC-Q for 15 min at room temperature prior to assay
in the complex IV reaction. A parallel control with KCN (2 mM)
inhibited complex IV activity ≥95–100%. Complex IV activity was
the KCN sensitive activity. In the absence of mitochondria, DAH
or DOPAC-H reduced oxidized cytochrome C back to reduced cyto-
chrome C. This can create a competing back reaction since the com-
plex IV assay measures the oxidation of reduced cytochrome C to
oxidized cytochrome C producing an effect thatmimics inhibition (seeResults). Reduced cytochrome C (4.0 mM) was prepared in 20 mM
potassium phosphate buffer, pH 7.0, and reduced using 7.8 mM L-
ascorbic acid. This mixture was dialyzed for 16 h at 4 °C using 20 mM
potassium phosphate, pH 7.0, as dialysis buffer, aliquoted and stored
frozen at −80 °C.
2.10. Complex I/III: NADH: cytochrome C–oxidoreductase
Complex I/III speciﬁc activity was measured by monitoring at
550 nm the reduction of cytochrome C. Activity was expressed as nmol
of cytochrome C reduction/min/mg protein (E=19mM−1·cm−1). The
assay was modiﬁed from Birch-Machin et al. [26]. Brieﬂy, the assay
medium contained K2HPO4 (20 mM) pH 8.0, EDTA (0.5 mM), KCN
(2 mM), NADH (25 μM), and cytochrome C (50 μM). Mitochondria
(50 μg of protein)were added to initiate the reaction and the enzymatic
reduction of cytochrome C was measured for 3–5 min. Complex I/III
activity was inhibited by ≥95% by the complex I inhibitor rotenone.
Complex I/III activity was the rotenone (10 μM) sensitive activity.
2.11. Complex II/III: succinate: cytochrome C–oxidoreductase
Complex II/III speciﬁc activity was measured by monitoring at
550 nm the reduction of commercially available cytochrome C which
contains a mixture of reduced and oxidized forms (Sigma Chem. Co,
St. Louis MO.). Activity was expressed as nmol of cytochrome C
reduction/min/mg protein. DAH/DAQ or DOPAC-H/DOPAC-Q was
monitored for quinone formation just prior to use. Complex II/III
assay was modiﬁed from Ragan et al. [25]. Brieﬂy, the assay medium
contained K2HPO4 (20 mM) pH 7.4, EDTA (0.5 mM), KCN (2 mM),
succinate (pH 7.4) (20 mM), and cytochrome C (50 μM). Mitochon-
dria (50 μg/ml) were preincubated with succinate for 15 min at room
temperature. Cytochrome C was added to initiate the reaction and the
rate was measured for 3–5 min. The complex III inhibitors myxothia-
zol (60 μM) and antimycin A (.002 mg/ml) or complex II inhibitor
malonate (10 mM) inhibited activity by ≥90–95%. Complex II/III
activity was the inhibitor sensitive rate. In the absence of mitochon-
dria, DAH and DOPAC-H reduced oxidized cytochrome C. This artifact
added to the forward reaction. To adjust for this, a parallel control
with DAH/DOPAC-H plus inhibitors and mitochondria was also
monitored and the rate subtracted from samples with DAH/ DOPAC-
H. The mean non-enzymatic rate was 30.5±0.09 (mean percentage
±0.09 S.D., n from 3 separate experiments). In order to maintain
consistency and control for any reduced catechols present when DAQ
or DOPAC-Q was added to mitochondria, the assay was run in the
presence or absence of inhibitors and the non-enzymatic rate was
subtracted from the overall rate to obtain the corrected complex II/III
inhibited rate.
2.12. DA uptake in intact mitochondria
Isolated, intact rat brain mitochondria (approximately 0.4 mg
protein) were pre-incubated at either 0 °C or 30 °C for 5 min in 0.9 ml
of mitochondrial incubation buffer (see above), containing 4 μM each
clorgyline and pargyline (MAO A and B inhibitors, respectively),
100 μM mazindol (dopamine transport inhibitor), 10 μM Ro4-1284
(vesicular dopamine transporter inhibitor; kind gift of Hoffman-La
Roche, Nutley, N.J., U.S.A.), and 200 μM ascorbate (to prevent
dopamine oxidation). 3H-labeled dopamine (speciﬁc activity 28 Ci/
mmol) supplemented with cold dopamine to ﬁnal concentrations of
1–15 mM was added and incubations continued for another 10 min.
At the end of incubation, uptake was stopped by the addition of 5 ml
of ice cold incubation buffer. Mitochondria were washed extensively
with incubation buffer using a Brandel Cell Harvester Model M24R
(Gaitherburg, MD). Mitochondria collected on GF/F Whatman ﬁlters
presoaked with 0.5% polyethylamine, were extracted with 0.2 N
perchloric acid. Radioactivity from the acid extracted matrix was
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was eliminated by subtracting counts obtained at 0 °C from those at
30 °C. Results were reported as nmol dopamine per mg protein.
2.13. Statistical analysis
Statistical signiﬁcance was calculated using ANOVA one-way test
with the Tukey post hoc test for comparison or by an unpaired student
t test using Graph Pad Instant version 3.0.
3. Results
3.1. DAQ and DOPAC-Q formation were monitored spectrophotometrically
at 480 nm and 400 nm respectively and quantiﬁed using a standard curve
Prior studies of the effects of DA on mitochondrial function have
not clearly differentiated reduced DA from oxidized DA and have
reported conﬂicting results [20–22,28,29]. In the current study, DA
was monitored at 480 nm [8] and DOPAC at 400 nm [24] and
standard curves made from tyrosinase-mediated fully oxidized DA
and DOPAC solutions were used to quantify the desired quinone
concentration at the time of exposure (Insets of Fig. 1A and B). When
a desired quinone concentration was reached, it was immediately
used in the reactions. A lack of absorbance at the respective wave-
length was interpreted as fully reduced DA or DOPAC. Past literature
has also been inconsistent regarding the amount of exposure time
of mitochondria to DA. In our study, NADH-oxidase and complex I
activities were measured with and without 30 min preincubation
periods at room temperature. No differences were found with pre-
incubation versus no pre-incubation when care was taken to ensure
that DA and DOPAC were fully oxidized or reduced at the time of
the assay. All remaining studies were measured with a 15 min pre-
incubation at room temperature.
3.2. Effects of reduced catechols DA and DOPAC on mitochondrial ETC
complex activities
3.2.1. NADH-oxidase activity was not attenuated by DAH or DOPAC-H
NADH-oxidase measures complex I, III and IV activities. NADH-
oxidase was not inhibited by DAH or DOPAC-H at 1 mMwith a 30 min
pre-incubation (Fig. 1A and B and Table 1) or without a pre-incubation,
(data not shown). The results demonstrate that complex I, III and IV are
not inhibited by reduced DA or DOPAC and that time of exposure to the
catechols was not a factor when the catechols remained fully reduced.DAQ
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Fig. 1. The effect of reduced dopamine and DOPAC on NADH oxidase activity. NADH oxidation
brainmitochondria were exposed to (A) 1 mM reduced dopamine (DAH) or (B) 1 mM reduce
DOPAC-H were expressed as nmol of NADH oxidized/min/mg protein±SEM. Inset: Standard
as described in Materials and methods and were used to quantitate quinone formation prio3.3. Complex I activity was not altered by DAH or DOPAC-H
To further validate the lack of effect of DAH and DOPAC-H on
complex I, a spectrophotometric assay was used that isolates electron
ﬂow through complex I. Rotenone sensitivity (N95%) conﬁrmed the
bulk of electron ﬂow through complex I. Consistent with the NADH-
oxidase assay, complex I activity was not affected by DAH or by
DOPAC-H with a 30 min pre-incubation (Table 1) or with no pre-
incubation period (data not shown). The results demonstrate that
exposure to the reduced catechols did not affect complex I activity.
3.4. Complex II activity was inhibited by DAH but not DOPAC-H
Complex II activity was corrected for the non-enzymatic reaction
between DAH or DOPAC-H and DCPIP which masked inhibition as
described in Materials and methods (2.7). The corrected rates show
that complex II activity was inhibited 32.7±2.0 and 41.9±5.5%
(±SEM) by 500 μM and 1 mM DAH, respectively, with a 15 min pre-
incubation (Fig. 2A and Table 1). In contrast, complex II activity was
not signiﬁcantly affected by DOPAC-H (Fig. 2B and Table 1), although
there was a trend towards decreased activity. Reduced DA can under-
go oxidation to form ROS such as superoxide and hydrogen peroxide
[28]. When studies were carried out in the presence of superoxide
dismutase (SOD) (1U) and catalase (1U) (Cat), it was found that SOD
protected from DAHmediated inhibition by 52.6% indicating that ROS
generation was contributing to the inhibition of complex II by DAH.
3.5. DAH and DOPAC-H did not attenuate complex III activity
Complex III activity could not be independently assessed because
in control studies in the absence of mitochondria, DAH and DOPAC-H
reduced oxidized cytochrome C and added to the forward reaction
masking inhibition. This artifactual interference resulted in inconsis-
tent data that could not be corrected by subtraction in the presence
of inhibitors. Although the complex II/III assay also measures the
reduction of cytochrome C, unlike the complex III assay that requires
oxidized cytochrome C (Section 2.8), the complex II/III assay uses a
mixture of reduced and oxidized cytochrome C (Section 2.11). This
mixture did not react with DAH and DOPAC-H to the same extent as
oxidized cytochrome C and inhibitor corrected rates could be used to
determine and correct for the artifactual interference. DAH inhibited
complex II/III activity to a similar extent as was observed with
complex II alone (Fig. 2C). As with complex II, DOPAC-H did not
signiﬁcantly inhibit complex II/III (Fig. 2D). These ﬁndings suggest
that inhibition of complex II/III in the presence of DAH was due toDOPAC-Q
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wasmeasured spectrophotometrically as described inMaterials andmethods. Lysed rat
d DOPAC (DOPAC-H) for 30 min at room temperature prior to assay. Values for DAH and
curves for oxidized dopamine (DAQ) and oxidized DOPAC (DOPAC-Q) were generated
r to each individual assay.
Table 1
Effects of reduced and oxidized DA and DOPAC on ETC complex activities.
Mitochondrial ETC complex DAH DOPAC-H IC50 Values for DAQ±SEM IC50 Values for DOPAC-Q±SEM
NADH-Oxidase (I, III, IV) No effect at 1 mM No effect at 1 mM 158.5 μM±0.1 177.8 μM±0.1
Complex I No effect at 1 mM No effect at 1 mM 50.1 μM±0.036 181.9 μM±0.017
Complex II Signiﬁcantly inhibited at 500 μM and 1 mM No effect at 1 mM No effect up to 400 μM No effect up to 400 μM
Complex III No effect at 1 mM No effect at 500 μM 151.4 μM±0.086 109.6 μM±0.065
Complex IV Inhibited at 1 mM due to artifactual competing
back reaction between oxidized cytochrome C
and reduced dopamine
No effect at 1 mM No effect up to 250 μM No effect up to 400 μM
Summary of results for inhibition of mitochondrial electron transport chain (ETC) activities by reduced dopamine (DAH) and DOPAC ( DOPAC-H) and oxidized dopamine (DAQ) and
DOPAC (DOPAC-Q). IC50 values represent the means±SEM of three separate experiments run in duplicate for each assay.
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measures complex I, III and IV activities, was not affected by 1 mM
DAH or DOPAC-H (Fig. 1A and B) further supporting that complex III
was not inhibited by DAH or DOPAC-H.3.6. The effects of reduced DA and DOPAC on complex IV activity
Complex IV activity was not affected by 1 mM DOPAC-H, however;
it was signiﬁcantly inhibited by 1 mMDAH (activity 61% of control with
1 mM DAH) (Table 1 and Supplemental material Fig. 1). The inhibition
observed in the presence of DAH was not prevented by: (2U) SOD
plus (2U) Cat, MAO A or B inhibitors (10 μM) pargyline and (10 μM)
clorgyline, respectively or dithioreitol (DTT) (50 μM) (data not shown).
Control studies, in the absence of mitochondria, showed that DAH and
DOPAC-H reduced oxidized cytochrome C. Since complex IV activity
monitors the oxidation of reduced cytochrome C, the presence of DAH
in the assay creates a competing back reaction that could mimic
inhibition. This coupled with the ﬁnding that NADH oxidase activity,
which includes complex IV, was not inhibited by DAH or DOPAC-H
(Fig. 1A and B), suggested that DAH did not inhibit complex IV. Instead,
the inhibition observed by DAH in the complex IV activity assay wasComplex II
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Fig. 2. Complex II and II/III activity in the presence of reduced dopamine and DOPAC. Co
methods. Lysed rat brain mitochondria were exposed for 15 min at room temperature to (A
(DOPAC-H) prior to assay. Each value is the mean malonate sensitive activity±SEM and i
attenuated by DOPAC-H but was inhibited 32.7±2.0 and 41.9±5.5% by 500 μM and 1 mMD
15 min exposure at room temperature to (C) various concentrations of DAH or (D) DOPAC-H
mg protein. (*p, 0.05, different from control).likely an artifact due to an interaction between DAH and the product of
the complex IV reaction, i.e., oxidized cytochrome C.
3.7. Effects of oxidized catechols DA and DOPAC on mitochondrial ETC
complex activities
Oxidized DA and DOPAC did not produce internal artifacts
with any of the components of the ETC assays. However, to maintain
consistencies in assay methodology, for the reduced and oxidized
catechols, mitochondrial ETC activitiesweremeasured in the presence
or absence of the appropriate inhibitors.
3.8. NADH-oxidase was dose dependently inhibited by DAQ and DOPAC-Q
Immediate reaction of DAQ or DOPAC-Q with mitochondria, dose
dependently inhibited NADH oxidase activity with IC50s of 158.5±
0.01 and 177.8±0.10 (mean μM±SEM) , respectively (Fig. 3A and B
and Table 1). With a 30 min preincubation at room temperature with
DAQ, the IC50 was 150±3.7 μM (data not shown) indicating that once
DAQ was formed, time was not a factor. The results demonstrate the
potential involvement of complex I, III or IV in the inhibition asso-
ciated with DAQ and DOPAC-Q.D
Complex II
DOPAC-H
0
100
200
300
400
500
control
Co
m
pl
ex
 II
 A
ct
iv
ity
n
m
o
le
s D
CP
IP
re
du
ce
d/
m
in
/m
g
Complex II/III
DOPAC-H dose response
0
250
500
750
A
ct
iv
ity
n
m
o
le
s c
yt
oc
hr
om
e 
C
re
du
ce
d/
m
in
/m
g 
pr
ot
ei
n
1 mM
control 500 uM250 uM100 uM
B
mplex II activity was measured spectrophotometrically as described in Materials and
) various concentrations of reduced dopamine (DAH) or to (B) 1 mM reduced DOPAC
s expressed as nmol of DCPIP reduction/min/mg protein. Complex II activity was not
AH, respectively. Complex II/III activity was measured spectrophotometrically following
. Values are the mean±SEM and are expressed as nmol of cytochrome C reduction/min/
NADH-Oxidase
DAQ Dose Response
0
25
50
75
100
 *
*
*
10 uM 25 uM 50 uM 100 uM 250 uM
NADH-Oxidase
DOPAC-Q dose response
0
25
50
75
100
 *
 *
 *
 *
50 uM 100 uM 200 uM 400 uM 1mM
%
 in
hi
bi
tio
n
%
 in
hi
bi
tio
n
A B
Fig. 3. The effect of oxidized dopamine and DOPAC on NADH oxidase activity. NADH oxidation was measured in lysed rat brain mitochondria immediately following exposure to (A)
various concentrations of oxidized dopamine (DAQ) or (B) oxidized DOPAC (DOPAC-Q). Values are the mean±SEM and were expressed as % inhibition as compared with control
(*pb0.05, different from control). Activity was dose dependently inhibited by DAQ and DOPAC-Q.
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dependent manner
In order to determine the site of DAQ, DOPAC-Q inhibitory action
in the ETC, the activities of the individual complexes were studied. It
was found that complex I activity was inhibited in a dose dependent
manner by DAQ and DOPAC-Q when there was no pre-incubation
with IC50s of 50.1±0.036 and 181.9±0.01 (mean μM±SEM), respec-
tively (Fig. 4A and B and Table 1). The IC50s for DAQwith a 30 min pre-Complex I
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mitochondriawerepre-incubatedwithDAQ for30 min at roomtemperature, pelleted, and then co
topelleting, hence theenzymewasnot activated (thirdbarongraph).Values are themean±SEM.incubation was 50.0±1.4 μM. The results suggest that inhibition of
complex I was quinonemediated and as with NADH-oxidase, once the
quinone was formed time was not a factor.
3.10. Complex I inhibition by DAQ was not attenuated by the antioxidants
SOD and catalase and required activation for inhibition by DAQ
SOD and catalase failed to prevent the inhibition of complex I by
DAQ (Fig. 4C). This supports that complex I activity was inhibitedComplex I
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formation. To examine if inhibition was reversible and if activation
of complex I was necessary for DAQ mediated inhibition, mito-
chondria were pre-incubated with DAQ at room temperature for
30 min in the absence of substrate (Fig. 4D). Thereafter, in some
incubations, the enzyme was activated by addition of NADH and
activity was measured. Mitochondria were then pelleted, the
supernatant was removed and the pellet resuspended. Complex I
activity was then re-measured in the absence of any added DAQ.
Non-activated complex I mitochondria were pre-incubated with
DAQ for 30 min at room temperature, pelleted, resuspended and
then complex I activity was measured. In this preparation, com-
plex I activity was not measured prior to pelleting; hence the
enzyme was not activated during exposure to DAQ. Complex I
activity was only inhibited when DAQ exposure occurred during the
active oxidation of NADH by complex I, suggesting that there was
unmasking of a site sensitive to either DAQ or alternatively the
semiquinone.3.11. Complex II activity was not affected by oxidized DA or DOPAC
In contrast with the reduced catechols, the results show that
oxidized DA (Fig. 5A and Table 1) or DOPAC (Fig. 5B) did not inhibit
complex II activity. The lack of effect of DAQ and DOPAC-Q on complex
II activity further supports that ROS generation during redox
chemistry with DAH contributed to the inhibition of complex II by
the reduced catechol as observed in Fig. 2.Complex II
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Fig. 5. The effect of oxidized dopamine and DOPAC on complexes II and III activities. Complex
(A) 400 μMof oxidized dopamine (DAQ) or (B) 400 μMoxidized DOPAC (DOPAC-Q) for 15 m
expressed as nmol of DCPIP reduction/min/mg protein. Oxidized DA or DOPAC did not at
Materials and methods. Lysed rat brain mitochondria were exposed to (C) different concen
period at room temperature. Activity is expressed as nmol of cytochrome C reduction/min/m
was dose dependently inhibited by DAQ and DOPAC-Q.3.12. Complex III activity was inhibited by both DAQ and DOPAC-Q in a
dose dependent manner
DAQ and DOPAC-Q inhibited complex III activity in a dose depen-
dent manner with IC50s of 151.4±0.086 μM and 109.6±0.065 μM,
respectively (Fig. 5C and D and Table 1). Attempts to determine the
reversibility of complex III inhibition by DAQ were carried out similar
towhat was donewith complex I, however the results were unreliable
due to the sensitivity of complex III activity to pelleting and resus-
pension resulting in loss of activity in both control and DAQ treated
samples.
3.13. Oxidized DA and DOPAC do not attenuate complex IV activity
DAQ (up to 250 μM) and DOPAC-Q (400 μM) did not inhibit
complex IV activity (Table 1). Higher concentrations were not run
since the IC50 for overall inhibition of NADH-oxidase activity, which
includes complex IV was 158.5±0.01 μM for DAQ, and 177.8±
0.16 μM for DOPAC-Q (Fig. 3A and B and Table 1).
3.14. GSH protects against complex I/III inhibition by DAQ
Since DAQ and DOPAC-Q inhibited complexes I and III activities,
we studied the effects of antioxidants and a metal chelator on DAQ
mediated inhibition of combined complex I/III. We assayed complex I/
III activity with (200 μM) DA plus tyrosinase (25U), in the presence or
absence of the hydrogen peroxide remover catalase (1U) (Cat),
superoxide remover superoxide dismutase (SOD) (1U) plus (1U) Cat,D
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or the quinone scavenger reduced glutathione (1 mM) (GSH). Only
GSH provided signiﬁcant and nearly complete protection from DAQ
mediated inhibition (86±0.06 mean % of control±SEM for DA in
the presence of tyrosinase plus GSH versus 7%±0.06 for DA and
tyrosinase alone), while catalase, catalase/SOD, desferoxamine and
trolox were without effect (Supplemental material Fig. 2). When
added in the absence of DAQ, the antioxidants and metal chelator did
not affect complex I/III activity. The results suggest a role for catechol
quinones and/or oxidized DA products in mitochondrial ETC inhibi-
tion rather than ROS since of the agents tested, only GSH can prevent
and/or sequester quinone formation.
3.15. DA uptake by intact mitochondria
In previous work we showed that exposure of intact mitochondria
to DA signiﬁcantly inhibited O2 consumption [18,19] with a Km of
~7 mM. In the present study we found that DA can inhibit mito-
chondrial function in lysed mitochondria by interaction with ETC
components with a Km in the low to moderate μM range. We next
addressed the question of whether DA can gain access to the
mitochondrial matrix. Well coupled, intact mitochondria (RCR N8)
were exposed to various concentration of 3H-labeled DA as described
in Materials and methods. The experimental paradigm used reduced
DA since previous work by the laboratory showed that exposure of
intact mitochondria to reduced DA resulted in inhibition of respiration
[19]. Secondly, in the case of loss of DA homeostasis, vesicular release
of DA into the cytosol, at least in terms of immediate exposure and
prior to its metabolism, would likely be to DA in its reduced form.
Following 10 min of incubation, mitochondrial matrix content of DA
increased in a dose-dependent fashion (Fig. 6). DA uptake was energy
dependent as only minimal counts were observed at 0 °C and ﬁnal
counts were corrected for this non-speciﬁc binding. Uptake was also
time dependent. Percentage of total DA uptake was measured at
various time points. At 1.25 min % of total uptake was 2.10±0.60, at
2.5 min it was 12.80±2.60, at 5.0 min it was 55.0±4.0, and uptake
was saturated by 10.0 min at 100.00±5.5, (mean percentage±SEM,
n is from 3 separate determinations). Reduced DA uptake was inde-
pendent of DA vesicular uptake, DA transporter activity, metabolism
by MAO A or B or DA oxidation since uptake was determined in the
presence of the VMAT inhibitor Ro4-1284, DAT inhibitor mazindol,1.0mM 5.0mM 10.0mM 15.0mM
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Fig. 6. Dopamine uptake by intact mitochondria. Dopamine uptake in isolated intact rat
brain mitochondria was determined by incubation for 10 min at 30 °C with 3H-labeled
dopamine as described in Materials and methods. Ascorbate (200 μM), Ro4-1284
(10 μM), mazindol (100 μM), clorgyline (4 μM) and pargyline (4 μM) were present to
block autoxidation, dopamine vesicular uptake, uptake by the dopamine transporter,
and metabolism of dopamine by MAO A or B, respectively. Radiolabeled dopamine
extracted from the mitochondrial matrix was quantiﬁed by scintillation counting and
corrected for non-speciﬁc binding by subtraction of counts from 0 °C incubations.
Uptake was expressed as concentration of mitochondrial dopamine in nmol/mg of
protein.MAO A and B inhibitors, clorgyline and pargyline, respectively and the
antioxidant ascorbate. These ﬁndings demonstrate that extramito-
chondrial DA can access the mitochondrial matrix.
4. Discussion
Three major general conclusions arise from this study which shed
light on the inconsistencies in the literature with regard to DA and its
effects on mitochondrial function. Firstly, data show that knowledge
of the redox state of the catechol is critical when determining the
inhibitory effect on mitochondrial function and the sites at which
interaction occurs. Secondly, time of exposure to the catechol is a
factor when there is a changing redox state. In the presence of a fully
reduced or oxidized catechol, the factor of time is removed. This
further exempliﬁes the need to know the oxidation/reduction state of
the catechol at the time of exposure. Thirdly, the oxidized catechols of
DA and DOPAC are more deleterious to ETC activities than are the
reduced forms.
The study is the ﬁrst to differentiate between reduced and oxidized
DA and DOPAC and measure their effects on each individual ETC
complex activity. Characterization of effects can be summarized as
follows: 1) reduced DA (DAH) inhibited only complex II activity of the
ETC, while reduced DOPAC (DOPAC-H) was without affect on any ETC
activities 2) oxidized DA and DOPAC (DAQ and DOPAC-Q respective-
ly) inhibited complexes I and III of the ETC with low to moderate μM
potencies and 3) DAQ irreversibly inhibited complex I only when
activated suggesting unmasking of a site sensitive to DAQ or the
semiquinone during active respiration.
The oxidation status of DA and DOPAC at the time of assay, as well
as, the time of exposurewas carefully assessed as bothmay contribute
to differing effects on activities. The results showed that when kept
reduced, DA and DOPAC did not inhibit NADH-oxidase activity with or
without a pre-incubation period of up to 30 min. In contrast, no pre-
incubation was necessary to fully inhibit NADH-oxidase when
exposure was carried out with the completely oxidized catechols.
Thus, time of exposure is a factor as DA becomes oxidized. At its
extremes, no inhibition of NADH-linked electron ﬂow occurs in the
presence of reduced DA or DOPAC, while robust and rapid inhibition is
observed with the oxidized catechols. Since the NADH-oxidase assay
measures the combined activities of complexes I, III and IV the effects
of the catechols were determined on individual ETC complex
activities. Complex I was not inhibited by either DAH or DOPAC-H
up to 1 mM regardless of a pre-incubation. Consistent with this,
Morikawa et. al., [20] reported no inhibition of complex I in mouse
brain mitochondria by 10 mM DA or 5 mM DOPAC, however, time of
exposurewas not indicated. Khan et al. [29] also found no inhibition of
complex I with DA in rat brain mitochondria with a 15 min pre-
incubation. In contrast Ben-Sachaar et al., reported inhibition of
complex I in rat brain mitochondria by DA and DOPAC with IC50s of
8.12±0 .75 μM [21] and 61.2±8.08 μM [22] respectively, with a
1 min pre-incubation. In these latter studies mitochondria were
pretreated with 2% digitonin. Digitonin is a detergent and may have
altered the mitochondrial membranes exposing sites sensitive to
inhibition that may not have been available in their normal state.
None of the studies mentioned above quantiﬁed for oxidized DA,
leaving open the possibility that the degree to which DA was oxidized
in the different preparations contributed to the disparate results.
In the current study, NADH-oxidase activity was dose dependently
inhibited by DAQ and DOPAC-Q with IC50s of 158.5 μM and 177.8 μM,
respectively, and complex I inhibited by DAQ with an IC50 of 50.1 μM.
Ben-Sachaar and colleagues [22] reported that desferoxamine
partially attenuated the DA mediated inhibition of complex I activity
consistent with a quinone mediated inhibition. Our results of quinone
mediated inhibition of complex I is also consistent with the studies of
Khan et al. [29] and Jana et al. [30] who reported inhibition of complex
I by 400 μM DA after an incubation period of 2 h. Khan et al. [29]
827A.H. Gautam, G.D. Zeevalk / Biochimica et Biophysica Acta 1807 (2011) 819–828measured quinone production after the 2 h incubation and found an
increase. Moreover, similar to our ﬁndings, Khan et al. [29] found that
5 mM GSH prevented DA mediated inhibition. GSH can keep DA in its
reduced form and prevent quinone formation or chelate quinones
already formed, thus further supporting a toxic role for quinones.
Although Khan et al. [29] monitored for quinone production, it was
not quantiﬁed making the concentration of quinone required for
inhibition uncertain.
Complex I was also dose dependently inhibited by DOPAC-Q with
an IC50 of 181.9 μM. In contrast, Jana et al. [30] found a marginal but
statistically signiﬁcant inhibition of complex I activity with 400 μM
DOPAC after 2 h incubation. DOPAC quinone formation was not
measured, however quinoprotein adduct formation was monitored
and none observed. It was concluded that DOPAC was far less toxic to
ETC activities than DA. It should be noted that in their study they air
oxidized DA and DOPAC. In the current study, DOPAC had to be
oxidized via tyrosinase because it did not air oxidize as did DA. Taking
into account the lack of DOPAC mediated quinoprotein formation and
method of oxidation in the Jana et al. [30] study; it is likely that DOPAC
had not oxidized under their assay conditions. Our ﬁndings would
indicate that in the oxidized state, DOPAC is similar in potency to DA
in inhibiting complex I.
The present study is the only study to investigate the effects of
reduced and oxidized DA and DOPAC on the individual activities of
complexes II and III. Malonate sensitive complex II activity was
signiﬁcantly inhibited by 1 mM DAH but not by DOPAC-H or oxidized
DA and DOPAC.Monitoring of themalonate sensitive rate is important
as DAH can pass electrons to DCPIP and mask inhibition. The
superoxide removing enzyme SOD signiﬁcantly protected from DAH
mediated inhibition, suggesting that ROS generation contributed to
the inhibition. In the current study the effects of the reduced catechols
on complex III activity could not be measured due to an internal
artifact created by an interaction between DAH, DOPAC-H and
cytochrome C that was not amenable to correction (see Materials
and methods and Results for details). Therefore, the effects of DAH
and DOPAC-H were assayed on complex II/III activity. Similar to
results with complex II, complex II/III activity was inhibited by DAH
with comparable potency, but not by DOPAC-H. This ﬁnding coupled
with the lack of effect of the reduced catechols on NADH oxidase
activity which includes complex III, would suggest that complex III
activity was not affected by DAH or DOPAC-H.
The inhibition of complex IV by 1 mM DAH in the present work
was concluded to be an internal artifact created by the interaction
between DAH and reduced cytochrome C mimicking inhibition (see
Results). NADH-oxidase activity, which includes complex IV activity,
was not attenuated by DAH. This ﬁnding supports that complex IV
activity was not affected by DAH. Ben-Sachaar et al. [22] reported no
inhibition of complex IV by DA up to 1 mMwith a 1 min incubation. In
the present study, oxidized DA up to 250 μM did not inhibit complex
IV activity. In contrast, Khan et al. [29] and Jana et al. [30] reported
62.8% and 57% inhibition of complex IV by 400 μMDA following 2 h of
incubation. Since the IC50 for DAQ inhibition in the NADH-oxidase
assay in our study was 158.5 μM, concentrations of DAQ greater than
250 μM were not tried. Higher concentrations of DAQ may have
inhibited complex IV. On the other hand, DAQ concentration was not
quantiﬁed in the Khan et al. [29] or Jana et al. [30] studies. Conse-
quently, it is possible that there was residual DAH present in the assay
medium. As we have observed, DAH can interact with the product of
the complex IV assay, i.e. oxidized cytochrome C producing a
competing back reaction that would mimic inhibition. Complex IV
activity was not affected by reduced or oxidized DOPACwith a 15 min
pre-incubation, which is in accordance with Jana et al. [30] who
reported only marginal effects on complex IV activity by 400 μM
DOPAC in rat brain mitochondria after a 2 h pre-incubation.
Another important ﬁnding from this study shows that in intact
mitochondria exposed to elevations in reduced DA, as might occur inthe cytosol of cells experiencing loss of DA homeostasis, the DA can
access the interior of mitochondria to inhibit ETC function. This
ﬁnding is supported by the work of van Laar et al. [31] who reported
that intact brain mitochondria exposed to 14C-DAQ covalently bound
to multiple subunits of complex I (75 kDa and 30 kDa subunits) and
complex III (ubiquinol-cytochrome c reductase core protein 1 and
Rieske Fe–S protein). Our work expands on these ﬁndings to show
that such interactions can lead to loss of ETC activities, speciﬁcally
complexes I and III. The ﬁndings are further supported by Berman and
Hastings [3], who reported that intact mitochondria exposed to DAQ,
but not DAH caused an initial uncoupling via a large increase in resting
state 4 respiration and decrease in active state 3 respiration followed
by increased swelling of mitochondria. The current study exposed
intact mitochondria to DA in its reduced form, whereas van Laar et al.
[31] exposed intact mitochondria to oxidized DA. In our characteri-
zation of the effects of oxidized and reduced DA onmitochondrial ETC
function, only oxidized DA inhibited complexes I and III. Since intact
mitochondria were exposed to DA in the presence of ascorbate, it is
unlikely that DA was oxidized prior to uptake. This would indicate
that both the reduced and oxidized forms of DA may gain entry into
mitochondria although it is uncertain whether this would involve
similar or differentmechanisms of transport as the uptakemechanism
remains to be investigated. DA oxidation occurs more readily at a pH
above 7.4. The mitochondrial matrix pH has been reported to be 7.98
in HeLa cells and 7.91 in rat cardiomyocytes [32]. Therefore, wewould
speculate that as reduced DA gains access to themitochondrial matrix,
it would likely oxidize and increase the potential to interact with ETC
proteins.
While much of the focus to date on catechols and mitochondrial
function has centered on DA, it is noteworthy that DOPAC has a similar
potency to DA as well as similar sites of interaction ([19] and the
current work). MAO is located on the outer mitochondrial membrane
and MAO metabolism of DA to DOPAC occurs rapidly once DA is
elevated. Elevation of DOPAC in the cytosol with its production in
close proximity tomitochondria raises the possibility that DOPACmay
be more deleterious to mitochondrial function when DA homeostasis
is lost. In support of this, Mosharov et al. [33] demonstrated that basal
levels of total catechols in rat chromaﬁn cells were 50–500 μM and
increased 5-fold when challenged with amphetamine to increase
cytosolic levels. Further, while DA levels were short lived, catechol
derivatives such as DOPAC were elevated in the cytosol for hours
following the amphetamine challenge. Our past ﬁndings of low mM
Kms for DA and DOPAC for inhibition of respiration in intact
mitochondria and low to moderate μM Kms for inhibition of complex
I and III activities in mitochondrial membranes directly exposed to
catechols would suggest that the ﬁndings from this study have
physiological relevance to ongoing cell damage in PD and further
indicate that loss of DA homeostasis could put mitochondria at risk for
accumulating damage either through elevation in DA or DOPAC.
Future studies thus need to address if DOPAC can access the
mitochondrial matrix similar to DA.
5. Conclusions
In conclusion, the ﬁndings from this study suggest thatmany of the
inconsistencies in the literature with regard to the sensitivity of ETC
complexes to inhibition by DA or DOPAC are due to the oxidation state
of the catechols at the time of exposure. Except for complex II, the
reduced catechols show no inhibitory effect on ETC activities. Further,
the presence of the reduced catechols and in particular DAH can
produce artifacts that can either mask inhibition (complex II and III)
or mimic inhibition (complex IV). Thus, care must be taken to ensure
that non-ETC related redox chemistry is taken into account. It was
further observed that pre-incubation time is only a factor when the
redox status of the catechol changes from reduced to oxidized. In
contrast with the reduced catechols, oxidized DA and DOPAC
828 A.H. Gautam, G.D. Zeevalk / Biochimica et Biophysica Acta 1807 (2011) 819–828inhibited complexes I and III. These studies support that mitochondria
may be a downstream target for damage by catechols when elevated
in the cytosol and may contribute to the ongoing progressive damage
associated with PD.
Supplementarymaterials related to this article can be found online
at doi:10.1016/j.bbabio.2011.03.013.
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